DZ2556A1 - Compositions nouvelles d'inhibiteur sélectif de réabsorption de sérotonine et d'un beta-bloquant. - Google Patents

Compositions nouvelles d'inhibiteur sélectif de réabsorption de sérotonine et d'un beta-bloquant.

Info

Publication number
DZ2556A1
DZ2556A1 DZ980166A DZ980166A DZ2556A1 DZ 2556 A1 DZ2556 A1 DZ 2556A1 DZ 980166 A DZ980166 A DZ 980166A DZ 980166 A DZ980166 A DZ 980166A DZ 2556 A1 DZ2556 A1 DZ 2556A1
Authority
DZ
Algeria
Prior art keywords
blocker
beta
serotonin reuptake
reuptake inhibitor
novel compositions
Prior art date
Application number
DZ980166A
Other languages
English (en)
Inventor
Paul John Cummings
Lan Frederic Tulloch
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2556A1 publication Critical patent/DZ2556A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DZ980166A 1997-07-11 1998-07-08 Compositions nouvelles d'inhibiteur sélectif de réabsorption de sérotonine et d'un beta-bloquant. DZ2556A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9714675.7A GB9714675D0 (en) 1997-07-11 1997-07-11 Novel composition

Publications (1)

Publication Number Publication Date
DZ2556A1 true DZ2556A1 (fr) 2003-02-15

Family

ID=10815744

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980166A DZ2556A1 (fr) 1997-07-11 1998-07-08 Compositions nouvelles d'inhibiteur sélectif de réabsorption de sérotonine et d'un beta-bloquant.

Country Status (26)

Country Link
EP (1) EP0996466A2 (fr)
JP (1) JP2002508003A (fr)
KR (1) KR20010021644A (fr)
CN (1) CN1262627A (fr)
AP (1) AP2000001728A0 (fr)
AR (1) AR016128A1 (fr)
AU (1) AU9340198A (fr)
BG (1) BG104119A (fr)
BR (1) BR9810996A (fr)
CA (1) CA2295822A1 (fr)
CO (1) CO4950552A1 (fr)
DZ (1) DZ2556A1 (fr)
EA (1) EA200000112A1 (fr)
GB (1) GB9714675D0 (fr)
HU (1) HUP0003074A3 (fr)
ID (1) ID24191A (fr)
IL (1) IL133869A0 (fr)
MA (1) MA24604A1 (fr)
NO (1) NO20000107D0 (fr)
OA (1) OA11276A (fr)
PE (1) PE99699A1 (fr)
PL (1) PL338017A1 (fr)
SK (1) SK72000A3 (fr)
TR (1) TR200000074T2 (fr)
WO (1) WO1999002142A2 (fr)
ZA (1) ZA986138B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
CA2348871C (fr) 1998-11-02 2009-04-14 John G. Devane Composition a liberation modifiee multiparticulaire
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
EP2283829A1 (fr) 2000-10-30 2011-02-16 Euro-Celtique S.A. Formulations d'hydrocodone à liberation lente
EP1793818A2 (fr) * 2004-09-17 2007-06-13 Neurocure Ltd. Pindolol pour le traitement du syndrome et du trouble dysphorique premenstruel
CN100469356C (zh) * 2006-09-08 2009-03-18 山东益康药业有限公司 复方阿替洛尔缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732335C2 (de) * 1976-07-27 1983-01-20 Sandoz-Patent-GmbH, 7850 Lörrach Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
EP0714663A3 (fr) * 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
WO1997006792A1 (fr) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentialisation de la production de serotonine
EP0792649A1 (fr) * 1996-02-29 1997-09-03 Eli Lilly And Company Traitement de l'insomnie

Also Published As

Publication number Publication date
PL338017A1 (en) 2000-09-25
PE99699A1 (es) 1999-12-21
NO20000107L (no) 2000-01-10
EP0996466A2 (fr) 2000-05-03
WO1999002142A3 (fr) 1999-04-15
EA200000112A1 (ru) 2000-10-30
CA2295822A1 (fr) 1999-01-21
CO4950552A1 (es) 2000-09-01
HUP0003074A3 (en) 2001-12-28
ID24191A (id) 2000-07-13
TR200000074T2 (tr) 2000-05-22
MA24604A1 (fr) 1999-04-01
IL133869A0 (en) 2001-04-30
OA11276A (en) 2003-07-31
AR016128A1 (es) 2001-06-20
SK72000A3 (en) 2000-12-11
AP2000001728A0 (en) 2000-03-31
BG104119A (en) 2000-12-29
HUP0003074A2 (hu) 2001-01-29
ZA986138B (en) 2000-01-10
NO20000107D0 (no) 2000-01-10
KR20010021644A (ko) 2001-03-15
BR9810996A (pt) 2000-08-08
AU9340198A (en) 1999-02-08
GB9714675D0 (en) 1997-09-17
WO1999002142A2 (fr) 1999-01-21
JP2002508003A (ja) 2002-03-12
CN1262627A (zh) 2000-08-09

Similar Documents

Publication Publication Date Title
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
CY2007024I2 (el) Kαινοφανη παραγωγα 3.3-διαφαινυλοπροπυλινων
FI955812L (fi) Siirrettävän tiedon koostumuksen säilyttäminen tukiaseman vaihdon yhteydessä
EE9600186A (et) Neurokiniini (tahhüülkiniini) antagonistid
EP0984692A4 (fr) Nouveaux inhibiteurs d'angiogenese
EE9700245A (et) 5-HT tagasihaarde inhibiitori kombinatsioon selektiivse 5-HT1A antagonistiga
TR199501132A2 (tr) Nörokinin karsitlari (antagonistleri).
DK1437359T3 (da) Hidtil ukendte 3,6-hemiketaler fra 9a-azalidklassen
EP0836382A4 (fr) Nouvelles cryptophycines
DE69417023D1 (de) Grubenstempel
IT1302243B1 (it) Sintesi dell'1,1,1,3,3-pentafluoropropano.
ITTO930610A0 (it) Composizione a base di 1,1,1,3,3,-pentafluorobutano e di cloruro di metilene per la pulitura e/o essicazione di superfici solide.
FI973229L (fi) Uusi farmaseuttinen koostumus
MA24604A1 (fr) Compositions nouvelles d'inhibiteur selectif de reabsorption de serotonine et d'un b-bloquant
EP0811014A4 (fr) Nouvelle bacteriocine, la piscicoline 126
DZ1965A1 (fr) Composition pharmaceutique nouvelle.
FR2753400B1 (fr) Caractere d' estampage articule
EP0824453A4 (fr) Nouvelles utilisations d'heptafluoropropane
FI960909A0 (fi) Bentsotiofeeniyhdisteet, välituotteet, koostumukset ja menetelmät
FR2714674B1 (fr) Agents hydrotropes et compositions les contenant.
BR7300677U (pt) Jogo fórmula-1
BR7300676U (pt) Jogo fórmula-1/S
ID21318A (id) Turunan-turunan 2,4-diaminopirimidin
FR2759289B1 (fr) Nouvelle application d'un depigmentant
UA1693S (uk) Набір етикеток "суми"